Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 177Lu-LNC1003 in PSMA-Positive mCRPC
NCT06237491Phase 1Not yet recruiting
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 1, open-label trial of 177Lu-PSMA-EB-01 in metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Yantai Lannacheng Biotechnology Co., Ltd. Primary endpoints: Safety of 177Lu-LNC1003 Injection up to 2 years, Dose-Limiting Toxicities and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
177Lu-PSMA-EB-01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06237491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237491.